Table 1

Baseline characteristics of the randomised patients

Home, N=33Hospital, N=34P value
Age, years63.6±8.663.1±7.00.80
Male sex, n (%)15 (45%)12 (35%)0.46
Active smokers, n (%)4 (12%)9 (27%)0.22
Packyears37.4±18.747.6±25.80.07
LTOT n (%)26 (79%)28 (82%)0.77
BMI, kg/m224.9±6.025.7±4.10.52
Inhaled long-acting beta-agonists, n (%)32 (97%)31 (91%)0.61
Inhaled long-acting anti-cholinergics, n (%)29 (88%)31 (91%)0.71
Inhaled corticosteroids, n (%)27 (82%)28 (82%)0.99
Morphine, n (%)11 (33%)8 (24%)0.43
Oral corticosteroids, n (%)15 (46%)12 (35%)0.46
Previous NIV experience during AECOPD, n (%)16 (48%)17 (50%)0.90
 Episodes of NIV for AECOPD, median (range)1 (1–3)1 (1–2)0.33
 Time span NIV for AECOPD—inclusion, days, median (range)106 (34–2555)172 (30–1825)0.19
Exacerbations, previous 12 months, median (IQR)4 (1–8)3 (1–5)0.31
Hospitalisations, previous 12 months, median (IQR)1 (0–2)1 (1–2)0.86
Rehabilitation, n (%)7 (21%)8 (24%)0.99
ESS score, points5.8±3.97.1±4.60.26
AHI (events/hour), median (IQR)2.9 (0.5–5.6)1.4 (0.8–2.9)0.38
Number of patients with AHI>15, n (%)1 (3%)2 (6%)0.99
  • Data are shown in mean and SD unless otherwise stated.

  • AECOPD, acute exacerbation of COPD; AHI, apnoea/hypopnea index; BMI, body mass index; ESS, Epworth Sleepiness Scale;IQR, interquartile range; LTOT, long-term oxygen therapy; NIV, non-invasive ventilation.